Zobrazeno 1 - 10
of 45
pro vyhledávání: '"G L Goll"'
Autor:
G. L. Goll, Trine Bjøro, Nils Bolstad, E. Lie, A. Wierød, David J. Warren, Joseph O. Sexton, J. E. Gehin, Tore K Kvien, S. W. Syversen, Liz Loli
Publikováno v:
Scandinavian Journal of Rheumatology. 50:445-454
Objectives: This study aimed to identify the therapeutic target concentration and frequency of anti-drug antibodies (ADAbs) in golimumab-treated patients with inflammatory joint disease (IJD). Method: Associations between golimumab concentration, ADA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d95a01ea6ea05407226a5a29896d080a
https://doi.org/10.1080/03009742.2021.1875040
https://doi.org/10.1080/03009742.2021.1875040
Autor:
I. Egeland Christensen, I. Jyssum, A. T. Tveter, J. Sexton, T. T. Tran, S. Mjaaland, G. B. Kro, T. K. Kvien, D. Worren, J. Jahnsen, L. A. Munthe, E. Haavardsholm, J. T. Vaage, G. Grodeland, F. Lund-Johansen, K. K. Jørgensen, S. W. Syversen, G. L. Goll, S. Aarrestad Provan
Publikováno v:
Annals of the Rheumatic Diseases. 81:116-117
BackgroundLimited data is available regarding long-term effectiveness of SARS-CoV-2 vaccines in patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapy. Whether the persistence of vaccine-induced humoral immunity agai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c27f5be5eca635a6c6c553dbe8c63234
https://doi.org/10.1136/annrheumdis-2022-eular.2054
https://doi.org/10.1136/annrheumdis-2022-eular.2054
Autor:
Elisabeth Gjefsen, Monica Wigemyr, G. L. Goll, Kristina Gervin, Maria Dehli Vigeland, Kaja Kristine Selmer, Hans Christian Dalsbotten Aass, Linda M. Pedersen, Lars Christian Haugli Bråten, Are Hugo Pripp, John-Anker Zwart, Kjersti Storheim, Elina Iordanova Schistad
Publikováno v:
RMD Open, Vol 7, Iss 2 (2021)
RMD Open
RMD Open
BackgroundLow back pain (LBP) is a leading cause of disability worldwide, but the aetiology remains poorly understood. Finding relevant biomarkers may lead to better understanding of disease mechanisms. Patients with vertebral endplate bone marrow le
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6c91ea6d7d0dd96318a2ab09a8e2da6
https://rmdopen.bmj.com/content/7/2/e001726.full
https://rmdopen.bmj.com/content/7/2/e001726.full
Autor:
G. L. Goll, Tore K Kvien
Publikováno v:
Arthritis Rheumatol
OBJECTIVE: To compare uptake in the ordering of biosimilars at a Veterans’ Affairs medical center (VAMC) to that at an academic medical center, where institutional incentives for infused medications differ. METHODS: We performed a cross-sectional s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56390df16d3ab3d5aa4c984e6492f8fd
https://doi.org/10.1002/art.41280
https://doi.org/10.1002/art.41280
Autor:
K Bjørlykke, M K Brun, M K Viken, G E Stenvik, R A Klaasen, J E Gehin, D J Warren, J Sexton, E A Haavardsholm, J Jahnsen, B A Lie, G L Goll, N Bolstad, S W Syversen, K K Jørgensen
Publikováno v:
Journal of Crohn's and Colitis. 16:i594-i595
Background Immunogenicity is a leading cause of treatment failure to TNF inhibitors. Genetic variations in HLA class II genes have been suggested to predispose to anti-drug antibody formation, but studies using high-resolution HLA typing as well as c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f91da4a8d07d133844834b6922d548fe
https://doi.org/10.1093/ecco-jcc/jjab232.817
https://doi.org/10.1093/ecco-jcc/jjab232.817
Autor:
E. K. Strand, I. S. H. Hatten, Kathrine A. Seeberg, Knut E.A. Lundin, Rolf Anton Klaasen, Tore K Kvien, Knut Tveit, C. Mørk, Espen A Haavardsholm, S. S. Hoie, G. L. Goll, Gert Huppertz-Hauss, Jon Hagfors, A. Poyan, Synøve Kalstad, B. Gulbrandsen, Geir Noraberg, Jørgen Jahnsen, David J. Warren, K. Waksvik, K. Ryggen, H. U. Rashid, Cecilia Vold, Ingrid Prytz Berset, Øivind Asak, Nils Bolstad, S. O. Frigstad, Bjørg Tilde Svanes Fevang, Bjørn Moum, Ulf Prestegård, Joseph Sexton, C. C. Zettel, I. P. Midtgard, Magne Henriksen, Ingrid M. Blomgren, M. Lorentzen, Roald Torp, Carl Magnus Ystrøm, K. Skjetne, T. J. Bruun, Katrine Dvergsnes, Pawel Mielnik, J. Krogh, Ø. Brenna, Inge C. Olsen, Inger Marie Jensen Hansen, S. Baigh, K. K. Jørgensen
Publikováno v:
Journal of Internal Medicine
BACKGROUND AND OBJECTIVES: The 52-week, randomized, double-blind, noninferiority, government-funded NOR-SWITCH trial demonstrated that switching from infliximab originator to less expensive biosimilar CT-P13 was not inferior to continued treatment wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed2e54f175da6e1a1bd891ec3eb52816
https://doi.org/10.1111/joim.12880
https://doi.org/10.1111/joim.12880
Publikováno v:
Revue du Rhumatisme. 86:115-118
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5d3fbc0ad449b62fb336ab4ebe8383f2
https://doi.org/10.1016/j.rhum.2018.09.007
https://doi.org/10.1016/j.rhum.2018.09.007
Autor:
E.S. Norli, Rolf Anton Klaasen, Tore K Kvien, J. E. Gehin, M.D. Mjaavatten, G. L. Goll, Silje W Syversen, David J. Warren, Nils Bolstad, Trine Bjøro
Publikováno v:
Rheumatology International
The aim of the study was to assess RF cross-reactivity to animal antibodies used in immunoassays, and to test if selected commercial immunoassays are vulnerable to interference from RF, causing false test results. Our study included samples from pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9dbf3d2e43b7421df9cd75339b7d8d16
http://hdl.handle.net/10852/92568
http://hdl.handle.net/10852/92568
Autor:
Nils Bolstad, Svanaug Skorpe, Yngvill Hovde Bragnes, Øystein Sandanger, Anne Julsrud Haugen, Roald Torp, Lars Normann Karlsen, Silje W Syversen, G. L. Goll, Ingrid M. Blomgren, David J. Warren, Camilla Zettel, Inge C. Olsen, Turid Thune, Christian Kvikne Dotterud, Brigitte Michelsen, Jørgen Jahnsen, Rune Johan Njålla, Geir Noraberg, K. K. Jørgensen, Pawel Mielnik, Carl Magnus Ystrøm, Kathrine A. Seeberg, J. E. Gehin, Joseph O. Sexton, Tore K Kvien, C. Mørk, Maud Kristine Aga Ljoså, Rolf Anton Klaasen, Trude Jannecke Bruun, Marthe Kirkesæther Brun, Espen A Haavardsholm, E. K. Strand
Publikováno v:
Journal of the American Medical Association (JAMA)
Importance Proactive therapeutic drug monitoring (TDM), defined as individualized drug dosing based on scheduled monitoring of serum drug levels, has been proposed as an alternative to standard therapy to maximize efficacy and safety of infliximab an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7427e8aee61a86b9681517c460490d0
https://hdl.handle.net/11250/3048675
https://hdl.handle.net/11250/3048675
Autor:
M. K. Brun, K. H. Bjørlykke, M. K. Viken, B. Stenvik, R. A. Klaasen, J. Gehin, D. J. Warren, J. Sexton, Ø. Sandanger, C. Mørk, T. K. Kvien, E. A. Haavardsholm, J. Jahnsen, G. L. Goll, B. A. Lie, K. K. Jørgensen, N. Bolstad, S. W. Syversen
Publikováno v:
Annals of the Rheumatic Diseases. 81:216.2-217
BackgroundImmunogenicity is a leading cause of treatment failure to TNF inhibitors, and also affects drug safety. Variations in HLA class II genes have been suggested to predispose to anti-drug antibody formation (ADA), but characterisation of biolog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c8fbdc3fa93a62d8cf10b85c30383228
https://doi.org/10.1136/annrheumdis-2022-eular.5020
https://doi.org/10.1136/annrheumdis-2022-eular.5020